carmustine has been researched along with Metastase in 108 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 9.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 9.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer." | 9.09 | Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. ( Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM, 2000) |
| "A phase II trial was conducted to determine the efficacy and toxicity of the addition of interferon-alpha 2b (IFN-alpha) to the chemotherapy combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV melanoma." | 9.08 | A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. ( Buzaid, AC; Poo, WJ; Schultz, MZ, 1997) |
| "Dacarbazine (DTIC) is the only single-agent approved by the Food and Drug Administration for treating metastatic melanoma." | 7.70 | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. ( Cognetti, F; Sega, FM; Serrone, L; Zeuli, M, 2000) |
| "One hundred twenty-one patients with disseminated malignant melanoma were treated with BCNU, vincristine, DTIC, and chlorpromazine (BVD)." | 7.65 | Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. ( Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK, 1977) |
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 5.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " We conducted a phase I trial of high dose paracetamol and carmustine (BCNU) in patients with advanced malignant melanoma to determine the optimal biological dose and the maximum tolerated dose (MTD) with the goal of increasing sensitivity to BCNU by GSH depletion." | 5.10 | Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. ( Chang, C; Chapman, PB; Fleisher, M; Hwu, WJ; Krown, SE; Livingston, PO; Pinto, JT; Williams, L; Wolchok, JD, 2003) |
| "Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer." | 5.09 | Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. ( Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM, 2000) |
| "A phase II trial was conducted to determine the efficacy and toxicity of the addition of interferon-alpha 2b (IFN-alpha) to the chemotherapy combination of dacarbazine (DTIC), carmustine (BCNU), cisplatin and tamoxifen (DBCT), in patients with stage III or IV melanoma." | 5.08 | A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. ( Buzaid, AC; Poo, WJ; Schultz, MZ, 1997) |
| "High-dose chemotherapy with a 3-day regimen of cyclophosphamide, cisplatin, and carmustine was used to treat mice bearing experimental lung metastases of mammary tumor cell lines with selectable markers (lines 66cl4 and 4TO7)." | 3.70 | Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents. ( Delmonico, L; Miller, BE; Miller, FR; Vistisen, K, 1998) |
| "Dacarbazine (DTIC) is the only single-agent approved by the Food and Drug Administration for treating metastatic melanoma." | 3.70 | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. ( Cognetti, F; Sega, FM; Serrone, L; Zeuli, M, 2000) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "Eight patients with advanced malignant melanoma were treated with high-dose melphalan (80-90 mg/m2) and BCNU (600-800 mg/m2)." | 3.67 | High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma. ( Havemann, K; Koeppler, H; Pflueger, KH; Seitz, R, 1989) |
| "The five-drug combination of fluorouracil imidazole carboxamide dimethyl triazeno, vincristine, bis-chloroethyl nitrosourea, and prednisone (FIVB + P) was given to 120 women with metastatic breast cancer." | 3.66 | A five-drug combination in the treatment of metastatic breast cancer. ( Falkson, G; Falkson, HC, 1981) |
| "A patient who had a pneumonectomy for lung carcinoma was treated with carmustine when brain metastases developed." | 3.66 | Pulmonary toxicity from carmustine (BCNU): a case report. ( Shah, S; Shane, SR; Weiss, RB, 1979) |
| "One hundred twenty-one patients with disseminated malignant melanoma were treated with BCNU, vincristine, DTIC, and chlorpromazine (BVD)." | 3.65 | Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. ( Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK, 1977) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "Sequential biopsies of metastases before and after streptozotocin were conducted to determine whether streptozotocin depletes tumor AT." | 2.68 | Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. ( Gerson, SL; Gordon, NH; Haaga, JR; Stellato, TA; Trey, JE; Willson, JK, 1995) |
| "173 patients with regional lymphatic metastases (n = 139) or distant disease (n = 34) were prospectively randomised, following resection of all clinically detectable tumour, to observation (n = 88) or adjuvant chemotherapy (n = 85)." | 2.67 | Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. ( Blumenson, L; Karakousis, C, 1993) |
| " Part II of the trial revealed that neither a higher dosage of ftorafur (2 g/m2/day X 5 days) nor the addition of vincristine to both regimens changed the previously obtained results significantly." | 2.65 | Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma. ( Arnold, H; Drings, P; Fritze, D; Geldmacher, J; Hartwich, G; Herrmann, R; Kempf, P; König, H; Meiser, RJ; Nedden, R; Pappas, A; Queisser, W; Schaefer, J; Schnitzler, G; Sievers, H; von Oldershausen, HF; Wahrendorf, J; Westerhausen, M; Witte, S, 1981) |
| "originates in the stomach." | 2.64 | Gastric cancer: current status of treatment. ( Carter, SK; Comis, RL, 1977) |
| "The incidence of brain metastases was neither lowered nor delayed by the presence of BCNU in regimens A and C." | 2.64 | Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. ( Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U, 1976) |
| "Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU." | 2.64 | Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). ( Berris, R; Hill, GJ; Parkin, P; Philpott, GW; Ruess, R, 1974) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| "Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy." | 1.30 | High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999) |
| "on post-surgical spontaneous metastases of a non-immunogenic tumour." | 1.28 | Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour. ( Acerbis, G; Cleris, L; Formelli, F; Parmiani, G; Rodolfo, M, 1992) |
| "Tegafur p." | 1.28 | Alternating chemotherapy in advanced gastric cancer. A phase II study. ( Barón-Saura, JM; Berrocal, A; Feliu, J; Girón, CG; González-Baron, M, 1991) |
| "Seventeen patients with metastatic breast cancer were treated with a high-dose combination chemotherapy regimen and autologous bone marrow support." | 1.27 | High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. ( Andersen, J; Antman, K; Come, S; Eder, JP; Elias, A; Henner, WD; Peters, W; Schnipper, L; Schryber, S; Shea, T, 1986) |
| "Of 16 evaluable patients with breast cancer, 15 responded (six complete responses)." | 1.27 | High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. ( Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D, 1987) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | 1.26 | Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981) |
| "Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded." | 1.26 | Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine. ( Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ, 1977) |
| "Skin, lymph node, and soft tissue metastases more frequently responded to therapy, while hepatic, peritoneal, and osseous metastases responded with an intermediate frequency." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma. ( Klahr, C; Presant, CA; Van Amburg, A, 1977) |
| "Of 11 patients with measurable metastases from bronchogenic carcinoma, five had partial antitumor responses lasting 1." | 1.26 | Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results. ( Gatewood, D; Klahr, C; Olander, J; Presant, CA, 1976) |
| "Osseous, visceral, and cutaneous metastases responded equally well." | 1.26 | Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors. ( Klahr, C; Kolhouse, JF; Presant, CA, 1976) |
| "All patients had extensive metastases in soft tissues, intestines and, some of them, in bone." | 1.26 | [Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)]. ( Kleeberg, UR; Schreml, W, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 79 (73.15) | 18.7374 |
| 1990's | 16 (14.81) | 18.2507 |
| 2000's | 11 (10.19) | 29.6817 |
| 2010's | 2 (1.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pytlík, R | 1 |
| Belada, D | 1 |
| Kubáčková, K | 1 |
| Vášová, I | 1 |
| Kozák, T | 1 |
| Pirnos, J | 1 |
| Bolomská, I | 1 |
| Matuška, M | 1 |
| Přibylová, J | 1 |
| Campr, V | 1 |
| Burešová, L | 1 |
| Sýkorová, A | 1 |
| Berková, A | 1 |
| Klener, P | 1 |
| Trněný, M | 1 |
| Michot, JM | 1 |
| Mazeron, R | 1 |
| Dercle, L | 1 |
| Ammari, S | 1 |
| Canova, C | 1 |
| Marabelle, A | 1 |
| Rose, S | 1 |
| Rubin, E | 1 |
| Deutsch, E | 1 |
| Soria, JC | 1 |
| Ribrag, V | 1 |
| Levy, A | 1 |
| Ahmann, DL | 2 |
| Carr, DT | 1 |
| Coles, DT | 1 |
| Hahn, RG | 2 |
| Wolchok, JD | 1 |
| Williams, L | 1 |
| Pinto, JT | 1 |
| Fleisher, M | 1 |
| Krown, SE | 1 |
| Hwu, WJ | 1 |
| Livingston, PO | 1 |
| Chang, C | 1 |
| Chapman, PB | 1 |
| Lens, MB | 1 |
| Eisen, TG | 1 |
| Plotnikov, A | 1 |
| Tichler, T | 1 |
| Korenstein, R | 1 |
| Keisari, Y | 1 |
| Gajewski, TF | 1 |
| Sosman, J | 1 |
| Gerson, SL | 2 |
| Liu, L | 1 |
| Dolan, E | 1 |
| Lin, S | 1 |
| Vokes, EE | 1 |
| Schmitz, R | 1 |
| Krakamp, B | 1 |
| Troidl, H | 1 |
| Wong, RP | 1 |
| Baetz, T | 1 |
| Krahn, MJ | 1 |
| Biagi, J | 1 |
| Wainman, N | 1 |
| Eisenhauer, E | 1 |
| Lin, SH | 1 |
| Kleinberg, LR | 1 |
| Cohen, SM | 3 |
| Ohnuma, T | 1 |
| Cheung, T | 1 |
| Holland, JF | 3 |
| Hanna, MG | 1 |
| Key, ME | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Rubin, J | 1 |
| Schutt, AJ | 2 |
| O'Connell, MJ | 1 |
| Gertz, MA | 1 |
| Moertel, CG | 3 |
| Del Prete, SA | 1 |
| Maurer, LH | 1 |
| O'Donnell, J | 1 |
| Forcier, RJ | 1 |
| LeMarbre, P | 1 |
| Massner, B | 1 |
| Voss, I | 1 |
| Queisser, W | 2 |
| Drings, P | 2 |
| Fritze, D | 2 |
| Westerhausen, M | 2 |
| Schnitzler, G | 1 |
| Schaefer, J | 1 |
| Arnold, H | 1 |
| Geldmacher, J | 1 |
| Hartwich, G | 1 |
| Herrmann, R | 1 |
| Kempf, P | 1 |
| König, H | 1 |
| Meiser, RJ | 1 |
| Nedden, R | 1 |
| von Oldershausen, HF | 1 |
| Pappas, A | 1 |
| Sievers, H | 1 |
| Wahrendorf, J | 1 |
| Witte, S | 1 |
| Falkson, G | 5 |
| Falkson, HC | 3 |
| Drago, JR | 2 |
| Goldman, LB | 1 |
| Worgul, T | 1 |
| Gershwin, ME | 1 |
| Worgul, TJ | 1 |
| Antman, K | 4 |
| Ayash, L | 1 |
| Elias, A | 3 |
| Wheeler, C | 1 |
| Schwartz, G | 1 |
| Mazanet, R | 1 |
| Tepler, I | 1 |
| Schnipper, LE | 1 |
| Frei, E | 3 |
| Willson, JK | 1 |
| Haaga, JR | 1 |
| Trey, JE | 1 |
| Stellato, TA | 1 |
| Gordon, NH | 1 |
| Berd, D | 1 |
| Mastrangelo, MJ | 2 |
| Falkson, CI | 1 |
| Uys, A | 1 |
| Keren-Rosenberg, S | 1 |
| Karakousis, C | 1 |
| Blumenson, L | 1 |
| Zirvi, KA | 1 |
| Najjar, TA | 1 |
| Slomiany, BL | 1 |
| Merouani, A | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Archer, PG | 1 |
| Schrier, RW | 1 |
| Aabo, K | 1 |
| Thompson, JA | 1 |
| Gold, PJ | 1 |
| Fefer, A | 1 |
| Schultz, MZ | 1 |
| Buzaid, AC | 1 |
| Poo, WJ | 1 |
| Hoffmann, R | 1 |
| Müller, I | 1 |
| Neuber, K | 1 |
| Lassmann, S | 1 |
| Buer, J | 1 |
| Probst, M | 1 |
| Oevermann, K | 1 |
| Franzke, A | 1 |
| Kirchner, H | 1 |
| Ganser, A | 1 |
| Atzpodien, J | 1 |
| Miller, BE | 1 |
| Delmonico, L | 1 |
| Vistisen, K | 1 |
| Miller, FR | 1 |
| Fleming, DR | 1 |
| Goldsmith, GC | 1 |
| Stevens, DA | 1 |
| Herzig, RH | 1 |
| Bearman, S | 1 |
| Vredenburgh, J | 1 |
| Cagnoni, P | 1 |
| Shpall, E | 1 |
| Nieto, Y | 1 |
| Ross, M | 1 |
| Peters, W | 3 |
| Jones, R | 1 |
| Klein, JL | 1 |
| Rey, PM | 1 |
| Dansey, RD | 1 |
| Karanes, C | 2 |
| Du, W | 1 |
| Abella, E | 1 |
| Cassells, L | 1 |
| Hamm, C | 1 |
| Peters, WP | 3 |
| Baynes, RD | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Sega, FM | 1 |
| Cognetti, F | 1 |
| Negrin, RS | 2 |
| Atkinson, K | 1 |
| Leemhuis, T | 1 |
| Hanania, E | 1 |
| Juttner, C | 1 |
| Tierney, K | 1 |
| Hu, WW | 2 |
| Johnston, LJ | 2 |
| Shizurn, JA | 1 |
| Stockerl-Goldstein, KE | 2 |
| Blume, KG | 2 |
| Weissman, IL | 1 |
| Bower, S | 1 |
| Baynes, R | 1 |
| Dansey, R | 1 |
| Klein, J | 1 |
| Keilholz, U | 1 |
| Suciu, S | 1 |
| Eggermont, AM | 1 |
| Cao, TM | 1 |
| Shizuru, JA | 1 |
| Taylor, TL | 1 |
| Rizk, NW | 1 |
| Wong, RM | 1 |
| Padulles, J | 1 |
| Prats, J | 1 |
| Martínez-Mora, J | 1 |
| Boix Ochoa, J | 1 |
| Ferres, F | 1 |
| Marmor, JB | 1 |
| Lokich, JJ | 1 |
| Chawla, PL | 1 |
| Schabel, FM | 2 |
| Paoletti, P | 1 |
| Robustelli della Cuna, G | 1 |
| Knerich, R | 1 |
| Strada, MR | 1 |
| Carter, SK | 2 |
| Comis, RL | 2 |
| Weiss, RB | 1 |
| Shah, S | 1 |
| Shane, SR | 1 |
| Stephens, RL | 1 |
| Hoogstraten, B | 3 |
| Haas, C | 1 |
| Clark, G | 1 |
| Wara, WM | 1 |
| Sheline, GE | 1 |
| Costanzi, JJ | 2 |
| Bellett, RE | 1 |
| Laucius, JF | 1 |
| Bodurtha, AJ | 1 |
| McKelvey, EM | 2 |
| Luce, JK | 4 |
| Talley, RW | 4 |
| Hersh, EM | 3 |
| Hewlett, JS | 1 |
| Moon, TE | 2 |
| Greenspan, EM | 2 |
| Ratner, LH | 1 |
| Weiner, MJ | 2 |
| Vaitkevicius, VK | 3 |
| Bodey, GP | 2 |
| Lane, M | 1 |
| Aranha, GV | 1 |
| Grage, TB | 1 |
| Presant, CA | 3 |
| Van Amburg, A | 1 |
| Klahr, C | 3 |
| Olander, J | 1 |
| Gatewood, D | 1 |
| Beretta, G | 1 |
| Bonadonna, G | 1 |
| Cascinelli, N | 1 |
| Morabito, A | 1 |
| Veronesi, U | 2 |
| Carmo-Pereira, J | 1 |
| Oliveira Costa, F | 1 |
| Pimentel, P | 1 |
| Moon, JH | 1 |
| Gailani, S | 3 |
| Cooper, MR | 1 |
| Hayes, DM | 1 |
| Rege, VB | 1 |
| Blom, J | 1 |
| Maurice, P | 1 |
| Brunner, K | 1 |
| Glidewell, O | 1 |
| Quagliana, JM | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 2 |
| Lynch, RG | 2 |
| Medoff, G | 2 |
| Valeriote, F | 2 |
| Posner, JB | 1 |
| Shapiro, WR | 1 |
| Van Dyk, JJ | 2 |
| Wollner, N | 2 |
| Burchenal, JH | 2 |
| Lieberman, PH | 2 |
| Exelby, PR | 1 |
| D'Angio, GJ | 1 |
| Murphy, ML | 2 |
| Exelby, P | 1 |
| D'Angio, G | 1 |
| Kolhouse, JF | 1 |
| Kleeberg, UR | 1 |
| Schreml, W | 1 |
| Acerbis, G | 1 |
| Cleris, L | 1 |
| Rodolfo, M | 1 |
| Parmiani, G | 1 |
| Formelli, F | 1 |
| Feliu, J | 1 |
| Girón, CG | 1 |
| González-Baron, M | 1 |
| Berrocal, A | 1 |
| Barón-Saura, JM | 1 |
| Deichman, GI | 1 |
| Kashleva, HA | 1 |
| Kluchareva, TE | 1 |
| Matveeva, VA | 1 |
| Koeppler, H | 1 |
| Pflueger, KH | 1 |
| Seitz, R | 1 |
| Havemann, K | 1 |
| Schoen, HD | 1 |
| Wendt, T | 1 |
| Keymling, M | 1 |
| Lübke, HJ | 1 |
| Wörner, W | 1 |
| Karakousis, CP | 1 |
| Emrich, LJ | 1 |
| Eder, JP | 3 |
| Henner, WD | 3 |
| Schryber, S | 3 |
| Wilmore, D | 2 |
| Finberg, R | 2 |
| Schoenfeld, D | 1 |
| Bast, R | 1 |
| Gargone, B | 1 |
| Shea, T | 2 |
| Andersen, J | 2 |
| Come, S | 1 |
| Schnipper, L | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Veeder, MH | 1 |
| Elson, DL | 1 |
| Laurie, JA | 1 |
| Nelimark, RA | 1 |
| Chang, MN | 1 |
| Clamon, G | 1 |
| Sinkey, C | 1 |
| Jochimsen, P | 1 |
| Wagenknecht, L | 1 |
| Yardumian, H | 1 |
| Fewer, D | 1 |
| Wilson, CB | 1 |
| Boldrey, EB | 1 |
| Enot, KJ | 1 |
| Powell, MR | 1 |
| Tormey, DC | 1 |
| Leone, L | 1 |
| Kabakow, B | 1 |
| Minton, JP | 1 |
| Reyes, ES | 1 |
| O'Bryan, RM | 2 |
| Gastesi, RA | 1 |
| Hill, GJ | 1 |
| Ruess, R | 1 |
| Berris, R | 1 |
| Philpott, GW | 1 |
| Parkin, P | 1 |
| Costanza, ME | 1 |
| Nathanson, L | 1 |
| Lenhard, R | 1 |
| Wolter, J | 1 |
| Colsky, J | 1 |
| Oberfield, RA | 1 |
| Schilling, A | 1 |
| Reitemeier, RJ | 1 |
| Lewis, MB | 1 |
| Nunes, LB | 1 |
| Powell, DE | 1 |
| Shnider, BI | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Bonnet, JD | 1 |
| Brownlee, RW | 1 |
| Garin, AM | 1 |
| Lichinitser, MR | 1 |
| Moroz, LV | 1 |
| Bajetta, E | 1 |
| Gottlieb, JA | 3 |
| Rivkin, SE | 1 |
| Spigel, SC | 1 |
| Singhakowinta, A | 1 |
| Schlessinger, D | 1 |
| Kobayashi, GS | 1 |
| Einhorn, LH | 1 |
| Burgess, MA | 2 |
| Vallejos, C | 1 |
| Gutterman, J | 1 |
| Mavligit, G | 2 |
| Freireich, EJ | 2 |
| Gutterman, JU | 1 |
| McBride, CE | 1 |
| Einhorn, L | 1 |
| van Eden, EB | 1 |
| van der Merwe, AM | 1 |
| Freeman, AI | 1 |
| Sachatello, C | 1 |
| Gaeta, J | 1 |
| Shah, NK | 1 |
| Wang, JJ | 1 |
| Sinks, LF | 1 |
| Mayo, JG | 1 |
| Laster, WR | 1 |
| Andrews, CM | 1 |
| Palma, J | 1 |
| Freeman, A | 1 |
| Sinks, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer[NCT00028015] | Phase 2 | 18 participants (Actual) | Interventional | 2001-10-30 | Completed | ||
| Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.[NCT00390624] | Phase 2 | 20 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma[NCT00683670] | Phase 1 | 17 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
7 reviews available for carmustine and Metastase
| Article | Year |
|---|---|
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 2003 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Cellular heterogeneity in malignant tumors. The importance of clonal interaction on tumor evolution, response to chemotherapy and metastatic ability evaluated in experimental systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Communication; Clone Cells; Humans; Mic | 1996 |
Interactions of hyperthermia and chemotherapy in animals.
Topics: Alkylating Agents; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bleomycin; Carmu | 1979 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
Solid tumor chemotherapy: new drugs and horizons.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Carmustine; Doxorubicin; Drug Therapy, Combinati | 1974 |
31 trials available for carmustine and Metastase
| Article | Year |
|---|---|
Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carmustine; Cell Line, Tumo | 1972 |
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Carmusti | 2003 |
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2005 |
SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carmustine; Colorectal Neoplasms; Dose-Response Relation | 2006 |
Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1981 |
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marro | 1994 |
Modulation of O6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers.
Topics: Adult; Aged; Carmustine; Colorectal Neoplasms; DNA Repair; Drug Resistance; Drug Therapy, Combinatio | 1995 |
FIVB plus GM-CSF in metastatic colorectal cancer.
Topics: Adult; Aged; Carmustine; Colorectal Neoplasms; Diarrhea; Drug Evaluation; Drug Interactions; Female; | 1994 |
Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmusti | 1993 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; | 1997 |
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Comb | 1997 |
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1998 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 2000 |
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 2000 |
[Survival of children and results obtained with a new chemotherapic combination in disseminated neuroblastoma treatment (author's transl)].
Topics: Antineoplastic Agents; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphami | 1976 |
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Topics: Adolescent; Adult; Aged; Bone Marrow; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu | 1978 |
Gastric cancer: current status of treatment.
Topics: Adenocarcinoma; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ther | 1977 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System | 1976 |
Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma.
Topics: Adult; Aged; Amides; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; Humans; I | 1975 |
Adjuvant chemotherapy in high-risk malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Combined Modal | 1987 |
Phase II study of the combination of carmustine and 6-thioguanine in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1987 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
Triple combination chemotherapy of disseminated melanoma.
Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati | 1972 |
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Topics: Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Clinical Trials as Topic; Edema; Fluoxymeste | 1973 |
Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
Topics: Adult; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cyclohe | 1974 |
71 other studies available for carmustine and Metastase
| Article | Year |
|---|---|
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2015 |
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2016 |
Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Colonic Neoplasms; Flow Cy | 2005 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Female; Humans; | 1983 |
Immunotherapy of metastases enhances subsequent chemotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carcinoma, Hepatocellular; Carmusti | 1982 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1984 |
[Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carmustine; Drug Therapy, Combination; Female; | 1982 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; | 1981 |
Therapy for Nb rat tumor transplanted in athymic mice.
Topics: Adenocarcinoma; Androgens; Animals; Carmustine; Dactinomycin; Male; Mice; Mice, Nude; Neoplasm Metas | 1981 |
[Malignant melanoma].
Topics: Aminoimidazole Carboxamide; BCG Vaccine; Carmustine; Humans; Lymphatic Metastasis; Melanoma; Neck Di | 1981 |
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, | 1981 |
Combination chemotherapy of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma | 1995 |
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female; | 1993 |
Use of tumor lines with selectable markers in assessing the effect on experimental metastases of combination chemotherapy with alkylating agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmusti | 1998 |
Dose-intensive chemotherapy for breast cancer with brain metastases: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carboplati | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci | 1999 |
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmus | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemo | 2000 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
Pulmonary toxicity from carmustine (BCNU): a case report.
Topics: Autopsy; Brain Neoplasms; Carmustine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Meta | 1979 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
Topics: Carmustine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Ly | 1977 |
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasi | 1977 |
Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma.
Topics: Carmustine; Chlorpromazine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leu | 1977 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Ascites; Bone Neoplasms; Breast Neoplasms; Carmustine; | 1977 |
Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
Topics: Amphotericin B; Blood Platelets; Bone Marrow; Carmustine; Drug Therapy, Combination; Granulocytes; H | 1976 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; | 1976 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
A murine model for central nervous system leukemia and its possible relevance to human leukemia.
Topics: Amphotericin B; Animals; Brain; Carmustine; Central Nervous System Diseases; Disease Models, Animal; | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lu | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami | 1976 |
Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Carmustine; Cyclophosp | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Mel | 1976 |
Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
Topics: Animals; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administratio | 1992 |
Alternating chemotherapy in advanced gastric cancer. A phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Doxoru | 1991 |
Clustering of discrete cell properties essential for tumorigenicity and metastasis. II. Studies of Syrian hamster embryo fibroblasts transformed by Rous sarcoma virus.
Topics: Animals; Avian Sarcoma Viruses; Carmustine; Cell Transformation, Viral; Cells, Cultured; Cricetinae; | 1989 |
High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
[Chemotherapy and enteral nutrition in stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1988 |
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 1986 |
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1986 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Drug Evaluation; Female; Hu | 1985 |
[Chemotherapy of malignant melanoma].
Topics: Alkylating Agents; Amides; Antineoplastic Agents; Bleomycin; Carmustine; Cyclohexanes; Drug Therapy, | 1973 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Mumps virus and BCG vaccine in metastatic melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carmustine; Female; Humans; Imm | 1973 |
Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea.
Topics: Amides; Antineoplastic Agents; Bone Marrow; Carmustine; Drug Synergism; Humans; Imidazoles; Lymph No | 1972 |
Treatment of the patient with adenocarcinoma of unknown origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Autopsy; Carmustine; Female; Fluorouracil; Human | 1972 |
Extra-axial spread of medulloblastoma.
Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Carmustine; Female; Gastrointestinal Diseases; Humans; M | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
[Imidazole carboxamide in the treatment of disseminated melanoblastoma].
Topics: Amides; Carmustine; Humans; Hydroxyurea; Imidazoles; Lymphatic Metastasis; Melanoma; Neoplasm Metast | 1973 |
[Chemotherapy of malignant melanoma].
Topics: Antineoplastic Agents; Carmustine; Humans; Melanoma; Neoplasm Metastasis; Nitrosourea Compounds; Ski | 1973 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia.
Topics: Amphotericin B; Animals; Bone Marrow Cells; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; | 1974 |
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Dexameth | 1974 |
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Topics: Adult; Aged; Amides; Antibody Formation; Antineoplastic Agents; BCG Vaccine; Carmustine; Drug Therap | 1974 |
5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
Topics: Adult; Aged; Alkylating Agents; Amides; Carmustine; Drug Combinations; Female; Fluorouracil; Humans; | 1972 |
An analysis of Ewing's tumor in children at Roswell Park Memorial Institute.
Topics: Adolescent; Autopsy; Carmustine; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studie | 1972 |
Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Line; Cyclohexanes; Cyclophosphamide; Lu | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |
Treatment of metastatic Ewing's sarcoma with BCNU.
Topics: Adolescent; Adult; Bone Neoplasms; Carmustine; Child; Child, Preschool; Female; Humans; Injections, | 1972 |